Alginate and alginate lyase compositions and methods of use

Patent metadata

Field	Value
Publication number	US-2016199464-A1
Application number	US-201514966213-A
Country	US
Kind code	A1
Filing date	Dec 11, 2015
Priority date	Oct 12, 2006
Publication date	Jul 14, 2016
Grant date	—

Abstract

The invention features alginate and alginate lyase compositions and methods that are useful for the treatment of various conditions and diseases. The invention also provides kits and instructions for use.

First claim

1 - 23 . (canceled)

24 . A method for the selective dissolution of an occlusion in a subject, wherein the subject has received treatment with an alginate based biomaterial, the method comprising the steps of:
(i) administering to the subject an alginate based biomaterial to a targeted area; and (ii) administering to the subject a composition comprising alginate lyase to the targeted area of step (i); thereby providing selective dissolution of an occlusion in a subject.

25 . The method of claim 24 , wherein the selective dissolution of an occlusion occurs in a vessel not targeted for treatment.

26 . The method of claim 24 , wherein administering to the subject the composition comprising alginate lyase occurs after occlusion.

27 . The method of claim 26 , wherein administering the composition occurs 1 second to 1 week after occlusion.

28 - 31 . (canceled)

32 . A method for the selective control of bulking or remodeling in a subject, the method comprising the steps of:
(i) administering to the subject an alginate based biomaterial to a targeted area; and (ii) administering to the subject a composition comprising alginate lyase to the targeted area of step (i); wherein administration of the composition comprising alginate lyase provides selective control of bulking or remodeling in a subject.

33 . The method of claim 32 , wherein the subject is undergoing plastic or reconstructive procedures.

34 . The method of claim 32 , wherein the targeted area is the lung.

35 - 77 . (canceled)

78 . The method of claim 24 , wherein the composition comprising an alginate lyase further comprises a divalent metal chelator.

79 - 86 . (canceled)

87 . The method of claim 24 , wherein the alginate based biomaterial has a property selected from the group consisting of:
the alginate based biomaterial comprises D mannuronic acid and D guluronic acid; the alginate based biomaterial comprises an alginic acid; the alginate based biomaterial is polymerized prior to administration; the alginate based biomaterial is alginate, optionally wherein the alginate is:
obtained from the group consisting of: Macrocystis, Laminaria, Ascophyllum , Chlorophyceae, Phaeophyceae, Rhodophyceae, and Cyanophyceae;
obtained from Aminaria hyperborean;
obtained from Laminara digita;
obtained from Ascophyllum nodosum;
a bacterial alginate; and/or
obtained from a heterotrophic bacteria.

88 - 96 . (canceled)

97 . The method of claim 24 , wherein a divalent cation is administered with the alginate biomaterial.

98 . The method of claim 97 , wherein:
the divalent cation is selected from the group consisting of: Ca 2+ , Mg 2+ , Ba 2+ , Sr 2+ ; the divalent cation is a synthetic compound with divalent orientation; the divalent cation is administered simultaneously with the alginate biomaterial; and/or the divalent cation is administered in a liposome or a microbubble, optionally wherein the liposome is selected from the group consisting of: heat sensitive liposomes, ultraviolet sensitive liposomes and pH sensitive liposomes.

99 - 103 . (canceled)

104 . The method of claim 24 , wherein the composition comprising alginate lyase is administered locally.

105 . The method of claim 24 , wherein the composition comprising alginate lyase is administered systemically.

106 . (canceled)

107 . The method of claim 78 , wherein:
the composition comprising alginate lyase and the divalent metal chelator are co-administered, optionally from the same device, optionally wherein the device is selected from the group consisting of: a syringe, a microcatheter, a bronchoscope and an endoscope; the divalent metal chelator is administered after administration of the alginate based biomaterial; and/or the alginate lyase and divalent metal chelator are administered at a ratio of 99:1-1:99.

108 - 110 . (canceled)

111 . The method of claim 24 , wherein:
the composition comprising alginate lyase is administered at a dose of 1 nanoliter per kg body weight to 50 mL per kg body weight; the alginate lyase is a bacterial alginate lyase, optionally wherein the bacterial alginate lyase is selected from the group consisting of: Flavobacterium, Burkholderia, Corynebacterium, Klebsiella, Photobacterium, Pseudoalteromonas, Pseudomonas, Rhodopirellula, Saccharophagus, Sphingomonas, Streptomyces, Vibrio , and Aspergillus; the alginate lyase is Flavobacterium alginate lyase; the alginate lyase is a transgenic alginate lyase; and/or the alginate lyase, or biologically active fragment thereof, comprises SEQ ID NO: 1, or a fragment thereof.

112 . (canceled)

113 . The method of claim 78 , wherein:
the divalent metal chelator is a proteinaceous metal chelator; is a non-proteinaceous metal chelator; is a calcium chelator; and/or is selected from the group consisting of: EDTA, DTPA, DMSA, citrate, tartrate, dimercaptol, penicillamine, deferoxamine, dithizone, cisplatin, and chlorophyll.

114 - 171 . (canceled)

172 . A method for dissolving a purified gel crosslinked with a divalent cation in a subject, the method comprising:
contacting in the subject the purified gel crosslinked with a divalent cation with a composition comprising a lyase, thereby dissolving the purified gel crosslinked with the divalent cation.

Assignees

• Univ Johns Hopkins

Inventors

• Barnett Bradley Powers
• Gailloud Philippe

Classifications

• A61K38/1875

  Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61L2300/254

  Enzymes, proenzymes · CPC title

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61L27/3882

  Hollow organs, e.g. bladder, esophagus, urether, uterus · CPC title